FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Gilenya News Channel
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
Everyone I've heard of
that's on Tysabri is doing
very well right now.
I'm Barfing Next Time I
Hear: "You Don't Look
Sick"
Dreams: My Journey with
Multiple Sclerosis
I'm Not Taking My MS
Meds & Getting Worse!
No More Shots
Due to Aubagio!
Medicine Damaged My
Hair Until I Started Doing
This...
My Stem Cell Journey
Medical Marijuana
Gave Me My Life Back
My Current Poison is
Paxil! It Makes Me Feel
Dried Up! I Can't Cry.
MS put me out of work:
Finally, a job again as a
columnist!
Migranes + MS =
1 Unhappy Camper
What It Feels Like
To Be Me
Being a columnist is my
dream! How often in life
do people get their
dreams to come true?
Here's Why I Love
Avonex
Don't Judge Me & My
MS
After misdiagnoses I was
fortunate enough to find
Dr. Timothy Vollmer!
I'm So Excited Because
I Just Started
Tecdifera
I've Had 47 Surgeries
and Amputation of My
Right Leg! Plus MS
I Live In Bonny Scottland
Where the Ducks Love It,
As There Is Rain, Rain, Rain
I Love to Write! It's one
thing I can do with
my MS!
I have been on
copaxone since 2001
The Monster is Attacking
Me Again! I'm Taking
Steroids For My Flare
How To Reduce The Side
Effects of Avonex And
Other Interferons
Before MS, I spent
nearly all day out in
the sun!
I checked in to the
hospital & I won't be
checking out soon!
My Neuro Wants
Me On Tecfidern
This Is My 1st Column, It's About Being In A Trial For Alemtuzumab (Campath)
This Pill Got Rid of
Our Migraines
My Relationship With
My Boyfriend Was
Fine Until I Got MS
Here's the Most Important Advice You'll Ever Get
About MS
DAMN STEROIDS!
By 4 Weeks I Gained
40 lbs
1 Year Ago My
Daughter
Committed Suicide!
The Ex: To Call or
Not to Call?
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week
July 2013   
September 2013   
October 2013   
June 2014   
July 2014   
January 2015   
February 2015   
March 2015   
April 2015   
May 2015   
July 2015   
March 2016   
April 2016   
May 2016   
June 2016   
HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center
OUR TERMS & CONDITIONS OF USE

Click to view 1280 MS Walk photos!
"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean
"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson
"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?

Friday

 

ECTRIMS Congress 2013: GILENYA REDUCES MS RELAPSE RATES COMPARED TO INTERFERONS OR GLATIRAMER ACETATE

 ECTRIMS Congress 2013

Novartis announced today findings from an international multiple sclerosis (MS) registry and a US health claims data base which showed the real-world superiority of Gilenya® (fingolimod) in reducing risks of relapses compared to standard therapies. These data confirm the positive results seen in clinical trials with Gilenya, and were presented at the ongoing 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark.


Relapses can make life unpredictable for patients with MS and they can potentially significantly advance an individual's level of disability. MS patients' clinical outcomes are regularly assessed and switching between disease-modifying therapies (DMTs), to reduce the rate or likelihood of a relapse, is a frequent treatment strategy.
Read more »

Labels: ,


 

ECTRIMS Congress 2013: Oral MS drug Gilenya® shows up to 71% reduction in annualised relapse rates

 ECTRIMS Congress 2013

Novartis showcases data from 13 abstracts on fingolimod

The data being presented for fingolimod at ECTRIMS/ACTRIMS highlight the Novartis clinical trial program for sphingosine 1-phosphate receptor (S1PR) modulators. Fingolimod targets MS via effects on the immune system and new pre-clinical data to be presented at ECTRIMS/ACTRIMS supports an
Read more »

Labels: , ,